A phase 1/2 trial of TG4050 in head and neck squamous cell carcinoma, run by Transgene, active and no longer recruiting.
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer is a phase 1/2 interventional study registered as NCT04183166 by Transgene, with 80 participants enrolled, started 2019-12-12 and due to reach its primary completion in 2027-12-30. Interventions recorded: TG4050.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.